The cystine-glutamate exchanger (xCT) promotes glutathione synthesis by catalyzing cystine uptake and glutamate release. The released glutamate may modulate normal neural signaling and contribute to excitotoxicity in pathological situations. Uncertainty, however, remains as neither the expression levels nor the distribution of xCT have been unambiguously determined. In fact, xCT has been reported in astrocytes, neurons, oligodendrocytes and microglia, but most of the information derives from cell cultures. Here, we show by immunohistochemistry and by Western blotting that xCT is widely expressed in the central nervous system of both sexes. The labeling specificity was validated using tissue from xCT knockout mice as controls. Astrocytes were selectively labeled, but showed greatly varying labeling intensities. This astroglial heterogeneity resulted in an astrocyte domain-like labeling pattern. Strong xCT labeling was also found in the leptomeninges, along some blood vessels, in selected circumventricular organs and in a subpopulation of tanycytes residing the lateral walls of the ventral third ventricle. Neurons, oligodendrocytes and resting microglia, as well as reactive microglia induced by glutamine synthetase deficiency, were unlabeled.
| I N TR ODU C TI ON
Glutamate is the major activator of excitatory neurotransmitter receptors in the mammalian central nervous system (CNS) and the extracellular glutamate concentrations must be kept low . While the mechanisms for glutamate removal have been identified (Danbolt, 2001) , the release mechanisms are not yet fully characterized (Baker, Xi, Shen, Swanson, & Kalivas, 2002; Marx, Billups, & Billups, 2015; Danbolt, Furness, & Zhou, 2016a) . One of the latter is system x 2 c , which mediates glutamate release in exchange for cystine uptake (Bannai, 1986) . Most, or all of, the system x 2 c activity in the brain is thought to be due to a heterodimer composed of a 4F2 heavy chain (CD98/Slc3a2) linked to the cystine-glutamate exchanger (xCT; Slc7a11) by a disulfide bridge (Sato, Tamba, Ishii, & Bannai, 1999) . The substrate selectivity is controlled by xCT while the heavy chain is common to several heteromeric transporters . System x 2 c has received considerable attention both because cystine uptake is considered important for synthesis of glutathione (Sato et al., 2005; Jiang et al., 2015; Seib, Patel, & Bridges, 2011) and because the accompanying glutamate release may be significant (Baker et al., 2002; De Bundel et al., 2011; Massie et al., 2011) by modulating neurotransmission and possibly by aggravating neurological disorders (for review see: Lewerenz et al., 2013; Boillee, Hewett, Knackstedt, and Lewerenz, 2015) .
There is, however, still uncertainty as neither the localization nor the tissue concentrations of xCT have been determined. Firstly, fairly high xCT expression levels are required if the above functions indeed rely on xCT. Secondly, the physiological roles of xCT also depend on its cellular and regional distribution. In situ hybridization did not provide evidence for a wide distribution in brain parenchyma, but rather revealed xCT mRNA in the leptomeninges, in some circumventricular organs and in select parts of the ventricular walls (Sato et al., 2002) . Further immunohistochemistry has given inconsistent results partly because of poor antibody specificity and partly because most of the studies have been based on cell cultures rather than intact brains (e.g., Van Liefferinge et al., 2016; Massie et al., 2015) . As a result, xCT protein is reported in neurons, astrocytes, microglia, oligodendrocytes and oligodendrocyte precursor cells (e.g., Soria et al., 2016; Burdo, Dargusch, and Schubert, 2006; La Bella, Valentino, Piccoli, and Piccoli, 2007) . One of the most cited studies (Pow, 2001 ) on xCT localization, however, suggests that system x 2 c is selective for astrocytes, but this study is based on antibodies to a substrate rather than the transporter itself and was performed before xCT knockout mice became available.
Here, we provide the first high-resolution immunohistochemical data validated with tissue from xCT knockout mice (xCT KO; Sato et al., 2005) as negative controls. We further provide quantitative data on the tissue content of xCT protein relative to excitatory amino acid transporter 3 (EAAT3) protein.
| M A TE RI A L S A ND M E TH ODS

| Materials
Sodium dodecyl sulfate (SDS) of high purity (>99% C12 alkyl sulfate) was from Pierce (Rockford, IL), and electrophoresis equipment were from Hoefer Scientific Instruments (San Francisco, CA) . N,N'-methylenebisacrylamide, acrylamide, ammonium persulfate, TEMED and alkaline phosphatase substrates (nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate) were from Promega (Madison, WI). Molecular mass markers for SDS-polyacrylamide gel electrophoresis and nitrocellulose sheets (0.22 lm pores, 100% nitrocellulose) were from Amersham (Buckinghamshire, UK). Prolong Gold AntiFade Mountant with DAPI (Cat. No. P-36935) was from Life Technologies (Carlsbad, CA). Paraformaldehyde and glutaraldehyde EM grade were from TAAB (Reading, UK). All other chemicals were obtained from Sigma (St. Louis, MO).
| Animals
All animal experimentation was carried out in accordance with the Formal approval to conduct the experiments described was obtained from the animal subjects review board of our institutions. Care was taken to avoid suffering and minimize the number of animals used.
Brain tissue for immunohistochemistry was obtained from young adult mice of both sexes that had been fixed by cardiac perfusion as described (Danbolt, Lehre, Dehnes, Chaudhry, & Levy, 1998) . The tissue used for estimating relative differences in regional xCT distribution by Western blotting was obtained from young adult female mice. The hippocampi used to compare xCT expression levels with those of EAAT3, and EAAT2, were from young adult mice of both sexes. The generation of mice lacking xCT and their genotyping, have been described in detail (Sato et al., 2005; Van Liefferinge et al., 2016; RRID: MGI:3608978). These mice have been backcrossed to C57BL/6J mice for at least 12 generations and kept in the animal facility of the Vrije Universiteit in Brussel. The Tie2-GFP (green) transgenic mice (Tg (TIE2GFP)287Sato/J; RRID:IMSR_JAX:003658) were obtained from Jackson Laboratories. The mouse expressing tdTomato red fluorescent protein in astrocytes was generated by crossing a mGFAP-Cre driver (B6.Cg-Tg(Gfap-Cre)77.7Mvs/2J; RRID: IMSR_JAX:024098) with a STOP-flox tdTomato reporter Ai9 (B6;129S6-Gt(ROSA)26Sortm9 (CAG-tdTomato)Hze/J; RRID: IMSR_JAX: 007905). To study whether xCT is expressed in reactive microglia, we examined brain sections from conditional glutamine synthetase knockouts which develop neurodegeneration accompanied by neuroinflammation (Danbolt et al., 2017) . A total of three pairs of brains were obtained from a colony set up to produce conditional glutamine synthetase knockout and wildtype mice.
| Antibodies
In-house developed anti-peptide antibodies against glutamate transporters were from the same batches as described previously. Because antibody batches may differ from each other (Danbolt, Zhou, Furness, & Holmseth, 2016b) , we identify the antibody batches produced in our laboratory by the unique identification number ("Ab#") they are given by our electronic laboratory information system (software provided by Science Linker AS, Oslo, Norway) as well as the Research Resource Identifiers (RRIDs) and a reference to the papers describing the production. The antibodies to xCT (Van Liefferinge et al., 2016) were raised in rabbits against peptides corresponding to residues 1-37 (Ab#618: MVRKPVVATISKGGYLQGNVSGRLPSVGDQEPPGHEK-amide; RRID: AB_2714118) and 471-502 (Ab#616: DKKPKWFRRLSDRITRTLQII-LEVVPEDSKEL-free acid; RRID:AB_2714106) of rat xCT and were
shown to be specific when tested both by immunoblotting and by immunohistochemistry on acetone fixed brain sections (Van Liefferinge et al., 2016) . The antibodies to EAAT1 were the rabbit anti-A522 antibody (Ab#314; Holmseth et al., 2009 ; RRID:AB_2314561) and a commercial mouse monoclonal anti-GLAST antibody (NCL-EAAT1; lot.
no.124104, Novocastra Laboratories, Newcastle, UK: Banner et al., 2002; RRID:AB_564088) . Both of these antibodies recognized a peptide (PYQLIAQDNEPEKPVADSET-amide) representing the C-terminal residues 522-541 of rat EAAT1 (Storck, Schulte, Hofmann, & Stoffel, 1992) . A third anti-EAAT1 antibody (Ab#286; Li, Zhou, and Danbolt, 2012 ; RRID:AB_2714072) was produced in sheep and directed to the N-terminal residues 1-25 (MTKSNGEEPRMGSRMERFQQGVRKRCamide) of rat EAAT1 (Storck et al., 1992) . The sheep antibodies to EAAT2 (Ab#8; Li et al., 2012 ; RRID:AB_2714090) were directed to rat EAAT2 (Pines et al., 1992) residues 493-508 (YHLSKSELD-TIDSQHR-amide), while the sheep antibodies to EAAT3, Ab#340 (Holmseth et al., 2005 ; RRID:AB_2714057) and Ab#565 (Holmseth et al., 2012a ; RRID:AB_2714058) were directed to residues 510-524 (VDKSDTISFTQTSQF-free acid) of rat EAAT3 (Bjørås et al., 1996) .
The other primary antibodies used were obtained commercially.
The mouse monoclonal antibodies were: anti-glial fibrillary acid protein (anti-GFAP; cat. no. G3893, lot.no. 083M4785; RRID:AB_477010); anti-synaptophysin (cat. no. S5768; RRID:AB_477523); anti-CNPase (cat. no. C5922; RRID:AB_476854); anti-a-smooth-muscle-actin (a-SMA; cat. no. A5228, lot. no. 065M4762V; RRID:AB_262054) and anti-b-tubulin (cat. no. T4026; RRID:AB_477577), all from SigmaAldrich (St. Louis, MO) and anti-glutamine synthetase (cat. no. MAB302, lot. no. 2571582; EMD Millipore, Billerica, MA; RRID: AB_2110656). The polyclonal antibodies were: Rabbit-Anti-Iba-1 (rbanti-Iba-1; cat. no. 019-19741; WAKO chemicals, GmbH, Germany; RRID:AB_839504); Chicken-Anti-Iba-1 (ch-anti-Iba-1; cat. no. 234006, lot. no. 234006/1; Synaptic Systems, Germany; RRID:AB_2619949) and Rat-anti-mouse-F4/80 (anti-F4/80; cat.no. 14-4801; eBioscience, San Diego; RRID:AB_467559).
The secondary antibodies and tertiary detection reagents were: 
| Electrophoresis and immunoblotting
Freshly frozen brain tissue was homogenized in 10-30 volumes of either water followed by centrifugation (Beckman JA20 rotor, 18,000 rpm, 48C, 10 min) to remove water soluble proteins prior to solubilization of the membrane proteins, or 10 mM sodium phosphate buffer with pH 7.4 (NaPi) with SDS (10 mg/ml) as stated. The samples were incubated (15 min) with or without reducing agent (30 mM DTT)
as stated prior to SDS-polyacrylamide gel electrophoresis and immunoblotting (Holmseth et al., 2009) . Briefly, the blots were first rinsed in phosphate buffered saline (PBS: 10 mM NaPi pH 7.4 and 135 mM NaCl) and then blocked (1 hr) with casein (50 mg/ml) in PBS before incubation with primary antibodies (at concentrations as stated) diluted in bovine serum albumin (BSA, 30 mg/ml) in PBST (PBS with 1 ml/L Tween 20 and 0.5 mg/ml NaN 3 ) over night at room temperature. Next, the membranes were rinsed (4 3 10 min) with PBST before incubation (1 hr) in secondary antibody solution (1:10,000 to 1:20,000), then rinsed (3 3 5 min) with PBST, and finally with PBS (2 3 5 min) before scanning.
The blots were examined for immunofluorescence using an infrared scanner (Licor Odyssey system, LI-COR Biotechnology-UK Ltd, Cambridge, UK). Densitometric data were extracted from the resulting 16-bit monochrome images (one image for each channel) by means of the gel analyzer tool included in our electronic laboratory information system (software provided by Science Linker AS, Oslo, Norway). Analysis of the extracted data was performed using Microsoft Excel (Microsoft Corporation, WA) and GraphPad Prism 4 (Graph-Pad Software Inc., San Diego, CA).
Because water soluble proteins have been reported to interfere with the binding of transporter proteins to the blotting membranes (Danbolt et al., 2016b) , we tested if water soluble proteins could interfere with detection of xCT. One mouse brain was homogenized in water, and divided in two equal aliquots. One aliquot was centrifuged (Beckman JA20 rotor, 18,000 rpm, 48C, 10 min) and the supernatant discarded. The ensuing pellet (referred to as membranes) and the untreated homogenate aliquot were brought up to the same volume by adding water, SDS (to 10 mg/ml) and NaPi (to 10 mM). The protein concentrations were estimated based on brain tissue mass assuming 100 mg total protein per gram wet weight and assuming that half of the protein is water soluble (Lowry, 1953; Lowry et al., 1954) . Removal of the latter did not appear to influence the xCT immunoreactivity recorded on the blots (Figure 1a ). This was repeated (Figure 1b Further, we found that xCT and CD98 were most efficiently separated when the disulfide link between them was reduced at room temperature rather than at 1008C (Figure 1c) . By applying different amounts of protein in different lanes, we ensured that we were working within the linear range (Figure 1a ,b).
To calculate the relative level of xCT compared with EAAT3 protein the raw densitometric data were plotted and linear regression was used to define a linear equation. The y-intercept was set as background level and this background was equally extracted from all the raw densitometric values before calculating the relative xCT/EAAT3 level.
| Immunohistochemistry
Mice were perfusion-fixed as described previously ; at least 0.1 ml per 10 g body weight). After cessation of all reflexes, the mice were perfused with 0.1 M NaPi to wash out blood, immediately followed by 4% formaldehyde in 0.1 M Membrane protein extracts (m) and whole brain protein extracts (w) from two more different mouse brains were prepared and immunoblotted with antibodies to xCT as described above. Note the linear relationship between the amount of protein loaded and the immunoreactivity detected (as assessed by raw densitometric values), and also note that the immunoreactivity was not significantly affected by removal of water soluble proteins. (c) The best effect of the reduction was seen when it was performed at room temperature (15 min; Lane 2) rather than at 1008C (2 min, boiling water bath; Lane 1). The two samples were loaded into neighboring lanes and this pair was repeated several times to produce several blot strips. The various strips were probed with antibodies to xCT (Ab#618, 0.5 mg/ml), EAAT2 (Ab#8, 0.3 mg/ml) and tubulin (Tub; anti-b-tubulin, 1:1,000) as indicated. The two left strips represent the same physical membrane double labeled and therefore scanned twice (in different infrared channels) producing two images. The dye front (DF) is indicated NaPi for 5 min. The relevant tissues were post-fixed in fixative (2-3 hr, room temperature). Sections (40 lm thick) were cut from the fixed unfrozen tissue using a Vibratome 1000 plus (Vibratome, Bannockburn, UK). Alternatively, the tissue was cryoprotected by transferring it to a solution consisting of 0.1 M NaPi with 10% (w/v) sucrose for 3-4 hr (48C), then in 0.1 M NaPi with 20% (w/v) sucrose (over night, 48C) and finally in 0.1 M NaPi with 30% (w/v) sucrose and 0.2 mg/ ml NaN 3 (over night, 48C) before freezing on dry ice and storage at 2808C until cutting with a Cryotome Microm HM450 (ThermoFisher Scientific).
Diaminobenzidine-peroxidase labeling was performed as described (Lehre, Levy, Ottersen, Storm-Mathisen, & Danbolt, 1995) . Briefly, the sections were pre-incubated in 1% hydrogen peroxide in 0.1 M NaPi, Immunofluorescent labeling was done as previously described . Briefly, the sections were rinsed (3 3 5 min) in TBST, treated with 1 M ethanolamine in 0.1 M NaPi pH 7.4 (30 min, room temperature), washed in TBST and blocked (1 hr) in TBST containing 10% NCS and 3% BSA followed by incubation (over night, room temperature) with primary antibodies diluted in 3% NCS and 1% BSA in TBST. Then sections were washed with TBST before incubation
(1 hr, room temperature) with secondary antibodies (1:1000). The sections were washed again with TBST and mounted with ProLong Gold antiFade mountant with DAPI.
| Preparation of xCT-EAAT3 chimeric protein
PCR: 10 ng mouse xCT cDNA (Sato et al., 1999) Ice-cold water containing 1 mM PMSF and 5 mM EDTA was added to each well and a cell scrape was used to lift the cells. The cell suspension was collected and centrifuged (13,000g, 10 min, 48C). The supernatant was discarded to remove water soluble proteins. The pellet was resuspended in 1% (w/v) SDS (containing 1 mM PMSF and 5 mM EDTA) to a final protein concentration of about 5 mg/ml, sonicated and stored at 2808C until it was used for immunoblotting as described above.
| Microscopy
Overview 
| Experimental design and statistical analysis
The validity of the present study depends on the specificity of the immunohistochemical procedures. As described in detail above, we have used antibodies both to the N-terminus and to the C-terminus of xCT with similar results. More importantly, we have used tissue from xCT knockout mice (Sato et al., 2005) processed in parallel as negative controls.
The images shown here demonstrate that labeling of wildtype mice is obtained when antibody concentrations and other parameters are set to minimize labeling of tissue from the knockout mice. As we have shown before, this is the single most important control (Holmseth et al., 2012b) . However, as outlined in our recently published strategy for immunohistochemical protein localization (Danbolt et al., 2016b) , it is also necessary to compare data obtained with different methods.
These considerations, although important, do not readily lend themselves to statistical analysis. All experiments that were not statistically analyzed were independently repeated a minimum of three times to ensure consistency and reproducibility. The data is presented as average 6 SEM. Statistically significant difference between group means were tested by one-way ANOVA, followed by Post hoc comparisons conducted with the use of Tukey HSD test (Figure 2d ). The statistical analysis was performed using IBM SPSS statistics 24 software.
| R E SU LTS
| Specific visualization of xCT protein in formaldehyde fixed mouse tissue
We have recently generated specific xCT antibodies (Van Liefferinge et al., 2016) . Here, an improved tissue processing protocol allowed detection of xCT in formaldehyde fixed tissue in which the tissue ultrastructure is well preserved. Both the antibody to the N-terminus (Ab#618) and the antibody to the C-terminus (Ab#616) of xCT, labeled tissue from wildtype mice without labeling tissue from xCT KO (Sato et al., 2005) processed in parallel ( Figure 2a ). Although the Ab#618 antibody gave stronger labeling than the Ab#616 antibody, the labeling patterns obtained with the two different antibodies were similar. Labeling with antibodies to EAAT1 was used as a positive control to check the quality of the xCT KO tissue.
As shown (Figure 2b ), xCT expression was detected in all brain regions, but at somewhat higher levels in the cerebral cortex (neocortex and hippocampus), thalamus, hypothalamus, and striatum than in the cerebellum and brain stem (Figure 2b ). Particularly high labeling intensities were seen in the leptomeninges surrounding the brain and along some larger blood vessels (e.g., Figure 2c , arrows and arrow heads, respectively), but there was also widespread labeling of brain parenchyma, as shown for neocortex, hippocampus, striatum and cerebellum ( Figure 2c 1-4 ) . In hippocampus the highest labeling intensities were observed in stratum lacunosum moleculare and in the molecular layer of the dentate gyrus ( Figure 2c 2 ). In the cerebellum, xCT was present in white matter and, with lower intensity, in the granule cell layer, whereas no labeling was 
| Within brain parenchyma xCT is expressed in astrocytes
Both the C-terminal antibody and the N-terminal antibody to xCT gave rise to patchy labeling of brain parenchyma. This was particularly FIG URE 2 Regional distribution of xCT protein in mouse brain. (a) Brain sections from wildtype (1/1) and xCT knockout (-/-) mice (littermates; 3 months old) were probed with antibodies to xCT (N-terminus: Ab#618, 1 lg/ml; C-terminus: Ab#616, 1 lg/ml) and developed with diaminobenzidine-peroxidase. Sections labeled with antibodies to EAAT1 (Ab#314, 0.1 lg/ml) were used as positive controls. (b) shows a section from a wildtype mouse processed as above using the Ab#618 antibody to xCT (1 lg/ml), and imaged at higher magnification. Note that xCT labeling was obtained in all brain regions, but with somewhat lower intensities in the cerebellum (C) than in the neocortex (X), hippocampus (H), hypothalamus, thalamus (T) and striatum (S). (c) Excerpts from Panel b presented with higher magnification. Note the particularly intense labeling of the leptomeninges (arrows Panels c 1 , c 4 ) and along some larger blood vessels (arrow heads Panels c 1 , c 2 , c 4 ), but also that the brain parenchyma itself was labeled. Also note the patchy labeling, which was especially prominent in the neocortex (c 1 ; X), hippocampus (c 2 ), caudate putamen (c 3 ; CPu) and nucleus accumbens (c 3 ; AcbC, AcbSh). In hippocampus, the most intensely labeled regions were stratum lacunosum moleculare (LMol) and the molecular layer of dentate gyrus (Mol). In cerebellum (c 4 ) xCT was detected in the white matter (wm) and, with lower intensity, in the granule cell layer (gcl), whereas the cerebellar molecular layer (ml) was xCT-negative. Also the white matter tracts of corpus callosum (cc; including forceps minor, fmi), fimbria of hippocampus (fi), commissura anterior (ac), stria terminalis (st), capsula interna (ic) and tractus opticus (opt) were labeled, although weaker than most of the grey matter regions (panels b and c). (d) The xCT protein levels in different brain regions were compared by immunoblotting (10 mg total protein per lane) with antibodies to both xCT (red; Ab#618, 0.5 mg/ml) and tubulin (green; anti-b-tubulin, 1:1,000) as illustrated with an image of a representative immunoblot. The labeling intensities were determined and xCT data was normalized to tubulin data, and expressed as percent (average 6 SEM; n 5 3 mice) of the values from neocortex. There was a statistically significant difference between group means as determined by one-way ANOVA F (6, 14) and not in sections from xCT KO (e.g., Figure 3d ). The diameters of the patches were similar to those of astrocyte domains (Oberheim et al., 2009 ). To test whether these patches actually represented astrocytes, 
| Co-localization of neuronal markers with xCT was not detected
To examine whether xCT-positive astrocyte branches could mask an eventual presence of xCT protein in neurons, we did immunofluorescence double labeling by combining antibodies to xCT with different neuronal markers known to be present in cell bodies and dendrites (EAAT3; Holmseth et al., 2012a) and terminals (synaptophysin), respectively. Where xCT and neuronal markers were present within the same areas, high resolution examination of the xCTpositive patches did not reveal any co-localization of xCT with markers for neuronal dendrites or somata (data not shown) or nerve terminals ( Figure 4h ). There was some labeling of neuronal nuclei, but as this was observed in the sections from both wildtype mice (e.g., Figure 3c ) and xCT KO (e.g., Figure 3d ), it was interpreted as cross-reactivity.
| Co-localization of oligodendrocyte marker with xCT was not detected
The strongest xCT labeling in the cerebellar parenchyma was in white matter ( Figures 2c 4 and 5a) . This raised the question of whether xCT could be expressed in oligodendrocytes. However, whereas double labeling for xCT and EAAT1 (using antibodies to both the N-and the C-termini of EAAT1) revealed co-localization of the two proteins (e.g., Figure 5b ), no co-localization of xCT and CNPase (an oligodendrocyte marker) was observed (Figure 5c ). Similarly, no co-localization of xCT and CNPase was detected in the corpus callosum, commissura anterior, capsula interna and chiasma opticum (data not shown). Thus, the observed weak xCT labeling in white matter tracts was due to expression in fibrous astrocytes. The present data did not provide evidence for xCT protein in oligodendrocytes.
| Co-localization of microglial markers with xCT was not detected
To examine whether xCT is expressed in microglia, microglia marker Iba-1 (Ito et al., 1998) 
| xCT is highly expressed in relation to leptomeninges and larger blood vessels
Intense xCT labeling was detected in the leptomeninges and along some blood vessels (e.g., Figures 2c, 3a ,c, 5a, and 6e,i). To examine whether endothelial cells express xCT, sections from Tie2-GFP transgenic mice were labeled for xCT. Confocal imaging, including both single section and Z-stacks scans, revealed that blood vessel related xCT was localized to cells clearly different from the endothelial cells (Figure 7a ).
FIG URE 3
Astrocyte heterogeneity with respect to xCT expression. Immunofluorescence labeling with antibodies to xCT (Ab#618, 1 lg/ml) reveals a patchy labeling pattern. (a) Montage of confocal micrographs from one section of a wildtype mouse hippocampus. (b) Single optical section scan from hippocampus CA1 from a section double labeled for xCT and GFAP (green; anti-GFAP, 1:200; astrocyte skeleton marker). Note that GFAP labels the astrocyte cytoskeleton and thereby reveals the centers of individual astrocyte domains. The approximate borders of two adjacent astrocyte domains are encircled to underline the variation in xCT labeling intensities between neighboring astrocytes. (c) Double labeling for xCT (red) and EAAT1 (green; NCL-EAAT1, 1:200) from hippocampus CA1 shows that the xCT-positive patches (*) are also positive for EAAT1 (green), which is a marker for astrocyte plasma membranes (Lehre et al., 1995) . Note that the xCT antibody does not label sections from xCT knockout (2/2; d) mice processed in parallel, with the exception for some unspecific binding to nuclei (e.g., in the pyramidal cell layer, P; upper part of Panel d). (e) Higher resolution excerpts (x63/1.40 oil immersion objective) from the boxes in (c). (f) xCT labeling (green) in a brain section from a transgenic mouse expressing tdTomato (red) under the mouse GFAP promoter (mGFAP:tdTomato). Note that xCT co-localizes with tdTomato in this reporter line, but that the astrocyte domains visualized by tdTomato expression (f, asterix) show quite a big variation in xCT labeling intensities. The image is from thalamus. DAPI (b, c 3 , f; blue) labels the nuclei. Abbreviations: O, stratum oriens; P, pyramidal cell layer; R, stratum radiatum; v, blood vessel. (Figures 2c 2 and 3a- c,e) is also seen in other wildtype mouse brain regions (green; xCT), as here shown for neocortex (a), thalamus (c) and the medial habenular nucleus (e). In these regions, the xCT-positive cells are positive also for the astrocyte marker EAAT1 (red; Ab#286, 0.5 lg/ml). Note that xCT-antibodies targeted to the N-terminus (a, Ab#618, 1 lg/ml) and to the C-terminus (Panels c and e, Ab#616, 3 lg/ml) give rise to the same labeling pattern. Panels b, d, and f show that, except for some unspecific nuclei staining, no xCT labeling is detected in the corresponding brain regions from xCT knockout (2/2) littermates imaged with the same confocal settings. (g) xCT (green; Ab#618, 3 mg/ml) is present in the fine astrocyte processes visualized by staining for EAAT1 (red; Ab#286, 1.5 mg/ml). In contrast, no co-localization could be observed with neuronal markers, as shown in (h) with double labeling for xCT (red; Ab#618; 1 mg/ml) and the nerve terminal marker synaptophysin (green; anti-synaptophysin, 1:1,000 shows one folium from a wildtype mouse cerebellum labeled with antibodies to xCT (red; Ab#618, 1 lg/ml) and to the C-terminus of EAAT1 (green; NCL-EAAT1, 1:200). The images are acquired in order to visualize the parenchymal xCT labeling implying that the stronger labeling related to the leptomeninges (indicated by arrows) and the vasculature (v; indicated by arrow heads) is oversaturated. Note that xCT is expressed in white matter (wm) and, albeit with lower intensity, in the granule cell layer. No xCT labeling is detected in the molecular layer (ml), which is highly EAAT1 positive. (b) shows a higher magnification image of double labeling for xCT (green; Ab#618, 1 lg/ml) and for the N-terminus of EAAT1 (red; Ab#286, 0.5 lg/ml). Note that the xCT labeling follows that of EAAT1 in white matter, suggesting that xCT is localized to fibrous astrocytes in the cerebellum. Similar to other brain regions, the xCT expression levels appear to vary greatly among astrocytes as xCT was not detected in all EAAT1-positive cells (e.g., arrows). Figure 8k ) were found to be xCT-negative based on observations from three different animals. The xCT antibodies however labeled some scattered non-ependymal cells in choroid plexus (Figure 8k; arrows) . Further, the ependymal lining of the aqueduct, the fourth ventricle and the proximal part of the central canal also were xCTnegative (Figure 8l-n) . Sections from xCT KO littermate tissue processed in parallel showed no xCT labeling related to ventricles and circumventricular organs (Figures 8g and 8p,r) .
| The content of xCT protein relative to EAAT3 protein in mouse hippocampus
Although the above immunohistochemistry and Western blotting indicated that xCT is both readily detectable with the antibodies used and widely expressed in the brain, none of these experiments gave information on the total amount of xCT protein. The high sensitivity of the confocal image acquisition allows proteins to be visualized even when expressed at very low levels. As we have in the past quantified the glutamate transporters Holmseth et al., 2012a) , we decided to compare the amount of xCT protein to the amounts of the glutamate transporter subtypes EAAT2 and EAAT3 by immunoblotting.
However, labeling intensities obtained with two different antibodies to two different proteins cannot be compared without a common reference.
Therefore, we created a chimeric xCT-EAAT3 protein ( Figure 9a ) and a chimeric xCT-EAAT2 protein (not shown). These chimeric proteins were run together with solubilized hippocampus tissue on immunoblots which were double labeled using antibodies to xCT and either EAAT3 ( This analysis revealed that the xCT/EAAT3 ratio equaled 0.75 6 0.07 (average 6 SEM; n 5 4 immunoblots like that in Figure 9b ). When the experiment was repeated with the chimeric xCT-EAAT2-protein, it was concluded that the EAAT2 levels are higher than the xCT levels by two orders of magnitude (data not shown) consistent with the EAAT2/EAAT3 ratio previously reported (Holmseth et al., 2012a) .
FIG URE 6 xCT was not detected in Iba-1 (microglia marker) positive cells, neither in normal mouse brain nor in the glutamine synthetasedeficient mouse hippocampus. (a and b) Immunofluorescent double labeling for xCT (red; Ab#618, 1 lg/ml) and microglia marker Iba-1 (green; ch-anti-Iba1, 1:500) in young adult wildtype mouse brain. At lower magnification (a) note that the distribution of xCT positive cells (red) is clearly different from the distribution of the Iba-1 labeled microglial cell population (green), as here shown for hippocampus CA1. Examination at higher resolution (b; x63/1.40 oil immersion objective) reveals that where microglial cells are located within the same area as the xCT positive patches, xCT was not detected in Iba-1 positive structures, further indicating that the two proteins are localized in different cells. (c-j) Neurodegeneration and reactive microglia are observed in mice lacking glutamine synthetase in the cerebral cortex (GS cKO: Danbolt et al., 2017) . As shown here with Nissl stained sections from a pair of littermates (15 weeks old), the pyramidal cells in the wildtype (WT) hippocampus CA1 (c) have degenerated (arrow) in the GS cKO mice (d). Immunofluorescence labeling for xCT (red; Ab#618, 1 lg/ml) in another pair of sections shows loss (f; montage, GS cKO, 9 weeks) of the astrocyte domain-like xCT labeling pattern seen in brain parenchyma in wildtype mice (e; montage, WT, 15 weeks). The labeling is, however, mostly preserved in the leptomeninges and along blood vessels. Immunofluorescent double labeling with marker proteins to macrophages (green; anti-F4/80, 1:500) and microglia (red; rbanti-Iba-1, 1:500) in sections from the same 9 weeks old GS cKO mouse shows changed microglial morphology revealed by Iba-1 labeling and upregulation of F4/80 (h) compared with the wildtype littermate (g). Despite this strong microglial activation, no co-localization of xCT (red; Ab#618, 1 lg/ml) and Iba-1 (green; ch-anti-Iba1, 1:500) was observed (j: hippocampus CA1). Thus, xCT was neither detected in resting microglia (a, b, and i) nor in reactive microglia induced by glutamine synthetase deficiency (j). DAPI (a, b, and e-j; blue) labels the nuclei. Abbreviations: LMol, stratum lacunosum moleculare; O, stratum oriens; P, pyramidal cell layer; R, stratum radiatum; v, blood vessel. Scale bars, a: 100 lm; b: 5 lm; c-f: 100 lm; g-i: 20 lm; j: 10 lm [Color figure can be viewed at wileyonlinelibrary.com]
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The aims of the present study were to map the distribution and to estimate the tissue content of xCT protein in mouse brain.
The regional distribution of xCT described here is in good agreement with in situ hybridization data (Sato et al., 2002) showing that the highest xCT expression levels in the adult mouse brain are in the area postrema, the subfornical organ, the medial habenular nucleus, and in parts of the lateral walls of the ventral third ventricle. The in situ hybridization also revealed scattered xCT expressing cells in the hypothalamus (Sato et al., 2002) , but overall labeling of brain parenchyma was weak, raising the question whether xCT is expressed at physiologically relevant levels. Here, due to higher sensitivity, we were able to reveal widespread xCT protein expression throughout brain parenchyma. Quantitative analysis further confirmed that the in vivo xCT protein concentrations are considerable. (Zhang et al., 2014; Zeisel et al., 2015) , and also with an elegant study of the distribution of system x 2 c activity, which was mapped with antibodies to a system x 2 c substrate (aminoadipate) in rat brain slices (Pow, 2001) , before the generation of xCT knockout mice (Sato et al., 2005) . In agreement with our data, aminoadipate was found accumulated in astrocytes, but not in neurons or oligodendrocytes. The distribution of accumulated aminoadipate, however, did not reveal astrocyte heterogeneity like the xCT data presented here, possibly because gap junctions allow aminoadipate to diffuse from one astrocyte to another. Interestingly, aminoadipate accumulated also in Bergmann glial cells which we found to be xCTnegative. In accordance with our findings, xCT mRNA was absent from the Purkinje cell layer (which contains cell bodies of both Bergmann glia and Purkinje cells), whereas mRNA encoding CD98 was present (Sato et al., 2002) , possibly suggesting that Bergmann glia express another Slc7-type of transporter with affinity for aminoadipate.
The variability in xCT expression adds to the growing list of proteins contributing to astrocyte heterogeneity (Schitine, Nogaroli, Costa, & Hedin-Pereira, 2015 , Hu, Yuan, Wang, & Su, 2016 . We have, however, no way of testing whether the observed variability in astrocytic xCT expression represents stable properties of the astrocytes or whether this changes with the functional state of the tissue. It is, however, interesting to note that a similar variability in xCT expression is found in gliomas (Robert et al., 2015) .
| Expression of xCT in reactive microglia
As induction of xCT has been reported in response to a number of different stimuli (for review see Bridges R J et al., 2012; Lewerenz FIG URE 7 Strong xCT labeling surrounding some large blood vessels. (a) A section from a Tie2-GFP transgenic mouse expressing green fluorescent protein in the endothelium was labeled with antibodies against xCT (red; Ab#618; 1 mg/ml). a 1 shows a montage of two microphotographs from the surface of neocortex with strongly labeled leptomeninges (arrows). An xCT-positive blood vessel is seen below the surface, but note that the smaller branch derived from this is xCT-negative (a 1 , arrow head). a 2 and a 3 are excerpts from a 1 , shown with higher magnification. Note that xCT (red) was not seen co-localized with the endothelium (green). (b) Double labeling for xCT (red; Ab#618, 1 lg/ml) and a-smooth-muscle-actin (green; antia-SMA, 1:500) revealed that xCT-expressing cells along the blood vessels are localized externally to the a-SMA expressing cells in the blood vessel wall, as shown here from thalamus. The parenchymal xCT labeling appears weak in this figure because the intensity and gain were set to avoid oversaturation of the labeling related to the leptomeninges and blood vessels. DAPI (b; blue) was used for nuclei staining. Scale bars, a 1 : 20 lm; a 2 , a 3 and b: 5 lm [Color figure can be viewed at wileyonlinelibrary.com] show how xCT (red; Ab#618, 1 lg/ml) is distributed along a rostro-caudal axis related to the ventral part of the third ventricle. The xCT labeling in the ventricle lining were below detection limit in the rostral portion (a), but gradually appeared in more caudal portions (b, c, d , and e). (f) is an excerpt from (c). Tissue from xCT KO (2/2) did not show any xCT labeling related to the ventricular system when examined at corresponding Bregma levels (a representative image in g). xCT could not be detected in ependymal cells lining the dorsal part of the ventral third ventricle (h), the floor and lateral walls of the dorsal third ventricle (i) or the lateral ventricles (j, arrows) and was also not detected in ependymal cells of choroid plexus (k: here shown for the lateral ventricle), but in a few, scattered non-ependymal cells of choroid plexus (arrows) probably associated with meningeal or vascular structures. Note that the medial habenular nucleus (i: MHb) is strongly labeled. (l-n) xCT (green; Ab#618, 1 lg/ml) was not found present in the ependymal lining of the aqueduct in midbrain (l), the fourth ventricle (m; here shown for the ventricle floor) or the proximal central canal (n). (o-t) The circumventricular organs area postrema (o; AP) and subfornical organ (q; SFO) are highly positive for xCT (green; Ab#618, 1 lg/ml). No xCT labeling was detected in AP and SFO in sections from the xCT KO littermate (2/2; p,r, respectively). Higher magnification (s,t) revealed that xCT (green) is co-localized with EAAT1 (red; Ab#286, 0.5 lg/ml) also in these regions. The nuclei are labeled (blue) by DAPI. Abbreviations: 3V, third ventricle; 4V, fourth ventricle; AP, area postrema; Aq, aqueduct; Arc, arcuate hypothalamic nucleus; ArcMP, arcuate hypothalamic nucleus, medial posterior part; CC, central canal; CPu, caudate putamen; D3V, dorsal third ventricle; DM, dorsomedial hypothalamic nucleus; DTM, dorsal tuberomammillary nucleus; ME, median eminence; MHb, medial habenular nucleus; Pe, periventricular hypothalamic nucleus; PVP, paraventricular thalamic nucleus, posterior part; Sch, suprachiasmatic nucleus; SFO, subfornical organ; VMH, ventromedial hypothalamic nucleus. Where relevant, the distance from Bregma is given (in mm) in the upper right corner of each panel according to the mouse brain atlas (Paxinos and Franklin, 2001 ). Panels a, b, g, o, and p are montages of two confocal microphotographs each. Scale bars, a-e: 100 mm; g-r: 50 mm; f, s, and t: 10 mm [Color figure can be viewed at wileyonlinelibrary.com] et al., 2013; Dai, Noverr, Parsons, Kaleeba, & Qin, 2015; Massie et al., 2015) , the possibility exists that other cell types than astrocytes, microglia in particular, may under certain conditions start expressing xCT. Most evidence for microglial xCT expression comes from in vitro studies, but there are some reports on induced xCT expression in reactive microglia in vivo (for references see: Bentea et al., 2017) . Here, however, we did not detect xCT in reactive microglia from the glutamine synthetase-deficient mouse hippocampi, raising the question of whether the mode of activation determines if xCT expression is turned on. The part of the xCT protein sequence that corresponds to the synthetic peptide used to produce the Ab#618 xCT antibody is indicated in green. The chimeric xCT-EAAT3 cDNA construct was expressed in HEK293T cells, which were harvested in water, centrifuged to remove water-soluble proteins and solubilized in SDS (Chimera). Extracts from mock-transfected cells were produced as negative control (NC). (b) The above extracts were subjected to electrophoresis and immunoblotting together with extracts from the hippocampi of three different wild type mice (H1, H2, and H3; water soluble proteins removed). The amounts of protein loaded in each lane are indicated. The dye front (DF) and the lanes containing molecular marker proteins (M) are indicated. The blots were double labeled with antibodies to xCT (green; Ab#618, 0.5 mg/ml) and EAAT3 (red; Ab#340, 0.5 mg/ml) and scanned (LiCor Odessey infrared scanner) to obtain quantitative information. Both of the antibodies labeled the chimeric protein (yellow) and additionally labeled the different respective target proteins in the hippocampus extracts as they should. The mobilities of the labeled molecules in the latter extracts are as previously reported: about 35 kDa for xCT (Van Liefferinge et al., 2016) and close to 70 kDa for EAAT3 (Holmseth et al., 2012a) . When using the chimeric protein to normalize the labeling intensities obtained with the two antibodies, the number of xCT protein molecules were found to be similar to that of EAAT3 protein molecules: 0.75 6 0.07 (average 6 SEM; n 5 4 immunoblots) times lower [Color figure can be viewed at wileyonlinelibrary.com] 4.3 | Role of xCT in the supply of cystine for glutathione synthesis Glutathione (a tripeptide consisting of glutamate, cysteine and glycine) is essential in many detoxification processes, and impaired glutathione metabolism is linked to human disease (Dringen, Brandmann, Hohnholt, & Blumrich, 2015) . As cystine is reduced intracellularly to cysteine, xCT provides one of the components required for glutathione synthesis.
However, lack of xCT in mice does not seem to cause reduced glutathione levels or oxidative stress in vivo (De Bundel et al., 2011; Massie et al., 2011) .
In line with this, there is a redundancy in this system. Firstly, cysteine is not an essential amino acid and is produced in astrocytes via the transsulfuration pathway (McBean, 2012) . Secondly, while system x 2 c is probably the only transporter able to exchange cystine for glutamate, several transporters are capable of cystine transport (e.g., Slc7a9, Slc7a13, and Slc7a15; Fotiadis, Kanai, & Palacin, 2013; Fernandez, Torrents, Zorzano, Palacin, & Chillaron, 2005; Nagamori et al., 2016) , implying that the presence of other cystine transporters in brain remains a possibility. Further, there are several cysteine transporters in brain. Hence, if cystine is reduced to cysteine at the cell surface, cysteine can be taken up independently of system x 2 c . Transporters for cysteine comprise EAAT3 (Zerangue & Kavanaugh, 1996) which is selectively expressed in neurons (Holmseth et al., 2012a) , and the alanine-serine-cysteine transporter (ASCT1, Slc1a4; Arriza et al., 1993) which is expressed in astrocytes (Sakai, Shimizu, Koike, Furuya, & Watanabe, 2003) , as well as NTT4 (Slc6a17), SNAT1 (Slc38a1), SNAT2 (Slc38a2) and possibly others (Mackenzie & Erickson, 2004; Zaia & Reimer, 2009; Br€ oer, 2008; Fotiadis et al., 2013 .
In particular, EAAT3 may be as important as xCT in providing glutathione precursors considering that mice lacking EAAT3 have lower glutathione levels and age prematurely (Aoyama et al., 2006) .
| Concentrations of xCT protein and contributions to extracellular glutamate
The hypothesis that system x 2 c is an important mediator of glutamate release in normal tissue (Baker et al., 2002) was recently supported by the observation that absence of xCT induces a decrease in extracellular glutamate (De Bundel et al., 2011; Massie et al., 2011) . However, for xCT to be able to release such amounts of glutamate two conditions must be met: (1) There must be enough external substrate available for exchange. (2) The concentrations of xCT protein must be sufficient to provide significant exchange capacity relative to the capacity of the removal mechanisms. The capacity of the latter is high (Otis & Kavanaugh, 2000 , Bergles & Jahr, 1997 Marx et al., 2015) , but if the ambient glutamate levels are considerably lower than the K m of EAAT1-3 mediated uptake (Herman & Jahr, 2007; Herman, Nahir, & Jahr, 2011) , then even a modest xCT-mediated release might be functionally significant.
Substrate availability:
Because system x 2 c exchanges internal and external substrates in a 1:1 relationship (Bannai, 1986) , the rate of glutamate release depends, not only on the transporter proteins (density and kinetics), but also on the availability of extracellular substrates (Patel, Warren, Rhoderick, & Bridges, 2004; Bridges R J et al., 2012) . It has recently become clear that cystine, which is only present at low concentrations, is not the only endogenous substrate. Also a-aminoadipate (Chang, 1982) , homocysteate (Do, Benz, Sorg, Pellerin, & Magistretti, 1997) and cystathionine (Kobayashi et al., 2015) are able to exchange with intracellular glutamate via system x 2 c . The tissue content of cystathionine appears to be considerably higher than that of cystine (for references see: Kobayashi et al., 2015) . The reported Kmvalues are 0.081 mM for cystine and 0.16 mM for glutamate (Mccormick & Tunnicliff, 1998) , with the affinity for cystathionine being similar to that for glutamate (Kobayashi et al., 2015) .
Exchange capacity:
The exchange capacity of xCT depends both on the number of transporter molecules at the plasma membrane and on how fast they operate (the cycling time). The finding that mouse hippocampus contains similar amounts of xCT and EAAT3 proteins implies that xCT protein is robustly expressed (Holmseth et al., 2012a) : the xCT levels are much higher than the forebrain levels of EAAT4 , but two orders of magnitude lower than EAAT2 . However, as xCT is highly inducible (Massie et al., 2015) , both the total xCT protein concentration and the percentage that is targeted to the plasma membrane may differ depending on the situation. EAAT3 is expressed in the cell bodies and dendrites of most, if not all neurons and is thereby distributed in a plasma membrane surface area of 1.5 mm 2 per mm 3 tissue (stratum radiatum, hippocampus CA1, young adult Wistar rats: Holmseth et al., 2012a) . This plasma membrane surface area is quite similar to that of astrocytes (1.4 mm 2 per mm 3 tissue: data from the stratum radiatum, hippocampus CA1, young adult Wistar rats: Lehre and Danbolt, 1998) . As xCT is more selectively distributed, but expressed at comparable tissue concentrations, the xCT levels in highly expressing astrocytes must be higher than that of EAAT3 in neurons. Further, judging from labeling intensities, the expression levels in cells related to the leptomeninges, blood vessels, circumventricular organs and ventricular walls are probably even higher.
Unfortunately, the cycling time of xCT-mediated cystine-glutamate exchange is unknown. For comparison, the cycling times of EAAT2 and EAAT3 are around 30 glutamate molecules per second at V max (Otis & Jahr, 1998; Otis & Kavanaugh, 2000; Bergles, Tzingounis, & Jahr, 2002; Grewer & Rauen, 2005) and the GABA transporters appear to operate at similar rates (Mager et al., 1993; Sacher et al., 2002; Karakossian et al., 2005; Gonzales et al., 2007) . As the transport cycles of these groups of transporters (Zhou, Wang, Tzingounis, Danbolt, & Larsson, 2014) are probably more complex than that of xCT, it is legitimate to hypothesize that system x 2 c may be faster.
| CON CL U S I ONS
In mouse brain parenchyma, xCT is selectively expressed in scattered astrocytes throughout the brain. Further, especially strong xCT labeling is found in select blood/brain/CSF interface areas: in the OTTESTAD-HANSEN ET AL.
| 967 leptomeninges, along larger blood vessels, in some circumventricular organs and in tanycytes in parts of the walls of the ventral third ventricle. In the present study we did not find evidence for expression of xCT in microglia, oligodendrocytes and neurons in the normal adult mouse brain. Also reactive microglia in glutamine synthetase-deficient hippocampi were xCT-negative. This does not rule out low level expression, but as transporters are slow compared with ion channels, they must be expressed at fairly high numbers for their activity to be physiologically relevant (for discussion see: Danbolt et al., 2016b) . We estimated the total concentration of xCT in the hippocampus to be similar to the EAAT3 protein concentration within factor two. With the distribution of xCT being more limited than that of EAAT3, this implies high levels of xCT in some cells. 
